Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to talk through $6 million the company has secured through a strategic placement of 300 million new shares at $0.02 each.
The placement was supported by new and existing stakeholders, including cornerstone investors, the Merchant Biotech Fund and Dr Daniel Tillett, who will join the board as a non-executive director.
Key shareholders and company executives, including Carroll himself, also participated.
The funds will facilitate the accelerated clinical development of TRP-8803, an IV-infused psilocin formulation designed to address limitations associated with oral psilocybin dosing.
Benefits of TRP-8803 include faster onset, more controlled dosing and shorter intervention times. This aligns with Tryp’s ongoing efforts to explore the compound’s therapeutic potential in treating various conditions.
The recent Phase 1b study confirmed TRP-8803’s safety, bolstering plans for larger trials and potential product registration in Australia.
The placement, scheduled in two tranches, will enable Tryp to advance its clinical strategy. Merchant Group acted as lead manager for the placement, with shareholder approvals anticipated for tranche two in an upcoming General Meeting.
#ProactiveInvestors #TrypTherapeutics #ASX #ClinicalTrials, #Psilocin, #PsychedelicTherapy, #TRP8803, #Psilocybin, #MentalHealth, #BiotechNews, #Pharmaceuticals, #HealthInnovation, #MedicalResearch, #BiotechFunding, #ASXNews, #PsychiatricDisorders, #Investment, #BioPharma, #MedicalTrials, #DrugDevelopment, #IVTherapy, #HealthSolutions